EMBO CAPS® manufactures pharmaceutical capsules using a proprietary blend of Type B pharmaceutical-grade bovine and Type A pharmaceutical-grade porcine gelatines.
EMBO CAPS® is a range of highly customisable and secure encapsulation technologies that allow drug developers to achieve wide product diversification.
The solutions provide a variety of different drug delivery solutions, including plant fibre-cellulose capsules for patients with diet restrictions, capsules designed to minimise brittleness for moisture-sensitive or hygroscopic dosages, sodium lauryl sulfate (SLS) free capsules, and low-powder retention capsules for dry powder inhalation.
High-performance drug capsules with secure locking mechanism
The EMBO CAPS® range incorporates a patented design that maximises capsule performance and function. They are developed with a pre-lock size and configuration that minimises premature separation during shipping and storage, while maximising filling machine separation performance.
The capsule is also designed to prevent the capsule from moving to the lock position from pre-lock during shipping.
EMBO CAPS® by Suheung
The design also includes a computer-engineered dome radius that directs the closing force along the side wall of the shell to reduce denting or dimpling during capsule filling. The amount of air allowed to escape when closing is also optimised to provide a uniform closed capsule length, and the mechanical hoop strength of the cap is increased.
In addition, the capsules have a double-lock and zone of constant diameter to ensure the cap is engaged correctly.
Highly stable gelatine drug capsules for the pharmaceutical industry
EMBO CAPS® capsules are manufactured to optimise stability and do not need to be refrigerated in transport.
The range utilises high-grade raw materials, including gelatine that is sourced from Suheung subsidiary Geltech. In addition, stringent specification compliance and computerised raw material cross-blending ensures only powders that meet the exact requirements can reach the capsulation machines.
EMBO CAPS® carry a five-year expiration date and meet regulatory requirements for the pharmaceutical market.
Since its foundation in 1973, Suheung has focused on offering high-quality, empty capsules.
The company has its own equipment manufacturing capabilities and production sites, and the uniformity of its capsules is ensured by state-of-the-art, automated robotic and vision inspection systems.
Suheung also provides contract manufacturing services for the pharmaceutical and nutraceutical industries, presenting a wide range of dosage types and packaging options.
The purpose of this white paper is to compare the equivalence of empty pharmaceutical hard capsules with various traditional raw materials such as gelatin and non-traditional vegetable hydrocolloids.
The purpose of this MAPP is to establish the policy in the Office of Pharmaceutical Quality (OPQ) for a postapproval change in the supplier of a hard gelatin capsule shell.
This MAPP establishes the policy in the Office of Pharmaceutical Quality (OPQ) for a postapproval change in the supplier of a hard gelatin capsule shell.
Suheung Capsule has announced it will be attending CPhI Worldwide.
Suheung America Corporation has announced the release of the new EMBO CAPS® VG-ALPHA drug delivery system, an empty vegetarian capsule targeted for use in the pharmaceutical market.